X Challenges Australia’s Expanded Social Media Ban Enforcement Powers 
Microsoft Stock Jumps as Azure Growth, AI Revenue Beat Expectations 
TeamViewer Shares Fall Despite Profit Growth as ARR and Customer Base Decline 
Robinhood Q2 Earnings Beat Estimates, But HOOD Stock Falls as Investors Question Profit Quality 
Barclays Q2 Profit Beats Forecasts as Investment Banking Strength Offsets Higher Costs 
Qualcomm Stock Falls as Weak Q4 Forecast, Apple Revenue Decline Overshadow AI Data Center Growth 
Meta CEO Zuckerberg Opposes U.S. Ban on Chinese AI Models, Warns Against Overregulation 
GSK Unveils $2.52 Billion Cost-Cutting Plan to Accelerate Drug Pipeline 
Standard Chartered Beats Profit Forecasts as First-Half Earnings Rise 9% 
BHP, Port Hedland Unions Fail to Reach Wage Deal as Negotiations Continue 
TSMC Gradually Restarts Japan Chip Plant After Kumamoto Earthquake 
Meta-backed research finds exposure to ‘untrustworthy’ social media is rare. The fine print is less reassuring 
SpaceX Wins $1.6 Billion U.S. Space Force Launch Contracts for Falcon 9 Missions Through 2027 
World game at war: why some European nations have threatened a World Cup boycott 
Unilever Raises 2026 Sales Outlook After Strong Q2 Volume Growth 
Starbucks Stock Jumps as Q3 Earnings Beat, Sales Growth Drives Higher 2026 Outlook 
Sony Eyes $1.3 Billion Tamron Acquisition as Lens Maker Reviews Offer 
CAMBRIDGE, Mass., May 08, 2018 -- Evelo Biosciences, Inc. (Nasdaq:EVLO) (“Evelo”) today announced the pricing of its initial public offering of 5,312,500 shares of common stock at a public offering price of $16.00 per share, before underwriting discounts and commissions. In addition, Evelo has granted the underwriters a 30-day option to purchase up to an additional 796,875 shares of common stock at the initial public offering price, less the underwriting discounts and commissions, to cover over-allotments, if any. Evelo’s common stock is expected to begin trading on The Nasdaq Global Select Market on May 9, 2018 under the ticker symbol “EVLO.” All of the common stock is being offered by Evelo. The gross proceeds of the offering are expected to be $85 million, excluding any exercise of the underwriters’ option.
Morgan Stanley, Cowen and BMO Capital Markets are acting as book-running managers for the offering. JMP Securities is acting as lead manager for the offering.
A registration statement relating to the securities being sold in the offering has been declared effective by the Securities and Exchange Commission. This offering is being made only by means of a prospectus. Copies of the final prospectus relating to this offering may be obtained, when available, by contacting Morgan Stanley & Co. LLC, 180 Varick Street, 2nd Floor, New York, NY 10014, Attn: Prospectus Department; Cowen and Company, LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, Attn: Prospectus Department, or by telephone at (631) 274-2806; or BMO Capital Markets Corp., 3 Times Square, 25th Floor, New York, NY 10036, Attn: Equity Syndicate Department, by telephone at 800-414-3627, or by email at [email protected].
This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of, these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of such state or jurisdiction.
Contact
Evelo Biosciences
Stefan Riley
617-704-2333
[email protected]
